- Home
- BBAI vs MLYS Comparison
BBAI vs MLYS Comparison
Compare BBAI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAI
- MLYS
- Stock Information
- Founded
- BBAI 2020
- MLYS 2019
- Country
- BBAI United States
- MLYS United States
- Employees
- BBAI N/A
- MLYS N/A
- Industry
- BBAI EDP Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- BBAI Technology
- MLYS Health Care
- Exchange
- BBAI Nasdaq
- MLYS Nasdaq
- Market Cap
- BBAI 716.7M
- MLYS 609.7M
- IPO Year
- BBAI N/A
- MLYS 2023
- Fundamental
- Price
- BBAI $3.04
- MLYS $12.34
- Analyst Decision
- BBAI Buy
- MLYS Strong Buy
- Analyst Count
- BBAI 4
- MLYS 2
- Target Price
- BBAI $3.17
- MLYS $30.00
- AVG Volume (30 Days)
- BBAI 46.2M
- MLYS 163.5K
- Earning Date
- BBAI 11-05-2024
- MLYS 11-11-2024
- Dividend Yield
- BBAI N/A
- MLYS N/A
- EPS Growth
- BBAI N/A
- MLYS N/A
- EPS
- BBAI N/A
- MLYS N/A
- Revenue
- BBAI $154,972,000.00
- MLYS N/A
- Revenue This Year
- BBAI $13.47
- MLYS N/A
- Revenue Next Year
- BBAI $16.32
- MLYS N/A
- P/E Ratio
- BBAI N/A
- MLYS N/A
- Revenue Growth
- BBAI 0.01
- MLYS N/A
- 52 Week Low
- BBAI $1.17
- MLYS $7.37
- 52 Week High
- BBAI $4.80
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- BBAI 52.81
- MLYS 47.76
- Support Level
- BBAI $2.42
- MLYS $11.19
- Resistance Level
- BBAI $3.82
- MLYS $12.57
- Average True Range (ATR)
- BBAI 0.57
- MLYS 0.80
- MACD
- BBAI -0.04
- MLYS -0.06
- Stochastic Oscillator
- BBAI 27.85
- MLYS 43.07
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.